{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:04Z","timestamp":1792804144176,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116050","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:25:07Z","timestamp":1760999107000},"page":"116050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["International expert consensus on the clinical integration of circulating tumor cells in solid tumors"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-6550","authenticated-orcid":false,"given":"Eleonora","family":"Nicol\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-0152","authenticated-orcid":false,"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas H.","family":"Stoecklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3309-7801","authenticated-orcid":false,"given":"Valeria","family":"Denninghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8757-3893","authenticated-orcid":false,"given":"Dominic G.","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann S.","family":"De Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Lianidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-5643","authenticated-orcid":false,"given":"Sabine","family":"Riethdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2480-3855","authenticated-orcid":false,"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-9353","authenticated-orcid":false,"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-4505","authenticated-orcid":false,"given":"Peter","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-3748","authenticated-orcid":false,"given":"Michail","family":"Ignatiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5932-8949","authenticated-orcid":false,"given":"Francois-Clement","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kasimir-Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-9054","authenticated-orcid":false,"given":"Maria Jose","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116050_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104483","article-title":"Unveiling the impact of circulating tumor cells: two decades of discovery and clinical advancements in solid tumors","volume":"203","author":"Reduzzi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2025.116050_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116050_bib3","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic Castration-Resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116050_bib4","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, Progression-Free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ebnurs-2020-103303","article-title":"What are delphi studies?","volume":"23","author":"Barrett","year":"2020","journal-title":"Evid Based Nurs"},{"key":"10.1016\/j.ejca.2025.116050_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","article-title":"Circulating tumor cells in breast cancer: clinical validity and utility","volume":"10","author":"Thomas-Bonafos","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib7","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an Individual-Level surrogate for survival in metastatic Castration-Resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic Castration-Resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic Castration-Resistant prostate cancer: a comparison with Prostate-Specific antigen across five randomized phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.37871","article-title":"Circulating tumor cell count and overall survival in patients with metastatic Hormone-Sensitive prostate cancer","volume":"7","author":"Goldkorn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2025.116050_bib11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice Variant-7 mRNA detection in circulating tumor cells of men with metastatic Castration-Resistant prostate cancer treated with First- and Second-Line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/PO.20.00200","article-title":"Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic Castration-Resistant prostate cancer","author":"Armstrong","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib13","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Prostate Cancer - Version 2.2025 \u2014 April 16, 2025."},{"key":"10.1016\/j.ejca.2025.116050_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/annonc\/mdp463","article-title":"Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents","volume":"21","author":"Tol","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib15","first-page":"e110","article-title":"Association between baseline circulating tumor cells, molecular tumor profiling, and clinical characteristics in a large cohort of Chemo-na\u00efve metastatic colorectal cancer patients prospectively collected","volume":"19","author":"Sastre","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S2468-1253(23)00146-2","article-title":"Clinical application of circulating tumour DNA in colorectal cancer","volume":"8","author":"Loft","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2025.116050_bib18","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2010.28.7045","article-title":"Evaluation and prognostic significance of circulating tumor cells in patients with Non\u2013Small-Cell lung cancer","volume":"29","author":"Krebs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdx156","article-title":"A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups","volume":"28","author":"Lindsay","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2019.04.019","article-title":"EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer","volume":"117","author":"Lindsay","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","article-title":"Efficacy of circulating tumor cell Count-Driven vs Clinician-Driven First-line therapy choice in hormone Receptor-Positive, ERBB2-Negative metastatic breast cancer: the STIC CTC randomized clinical trial","volume":"7","author":"Bidard","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.23.00456","article-title":"Overall survival with circulating tumor cell Count-Driven choice of therapy in advanced breast cancer: a randomized trial","volume":"42","author":"Bidard","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2023.41.16_suppl.1059","article-title":"Circulating tumor cells (CTCs) dynamics after CDK4\/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): a biomarker analysis of the PACE randomized phase II study","volume":"41","author":"Gerratana","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.eururo.2019.04.006","article-title":"Clinical utility of circulating tumour cell androgen receptor splice Variant-7 status in metastatic Castration-resistant prostate cancer","volume":"76","author":"Sharp","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116050_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3108","article-title":"Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis","author":"Janni","year":"2025","journal-title":"Clin Cancer Res OF1OF14"},{"key":"10.1016\/j.ejca.2025.116050_bib26","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.116050_bib27","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-22-3233","article-title":"PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic Castrate-resistant prostate cancer","volume":"29","author":"Gupta","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116050_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100299","article-title":"Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program","volume":"6","author":"M\u00fcller","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116050_bib29","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-14-1913","article-title":"Development of circulating tumor Cell-Endocrine therapy index in patients with hormone Receptor\u2013Positive breast cancer","volume":"21","author":"Paoletti","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116050_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and White blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"Ili\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260124","article-title":"PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer","volume":"16","author":"Darga","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2025.116050_bib32","doi-asserted-by":"crossref","first-page":"26112","DOI":"10.18632\/oncotarget.15345","article-title":"Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients","volume":"8","author":"Ilie","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2025.116050_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/clinchem\/hvad144","article-title":"Efficacy of lapatinib in patients with HER2-Negative metastatic breast cancer and HER2-Positive circulating tumor Cells-The DETECT III clinical trial","volume":"70","author":"Fehm","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2025.116050_bib34","unstructured":"Smilkou S., Ntzifa A., Tserpeli V., et al: Detection rate for ESR1 mutations is higher in circulating-tumor-cell-derived genomic <scp>DNA<\/scp> than in paired plasma cell-free <scp>DNA<\/scp> samples as revealed by <scp>ddPCR<\/scp>. Mol Oncol, 2025."},{"key":"10.1016\/j.ejca.2025.116050_bib35","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.3390\/cancers13194885","article-title":"Heterogeneity of circulating tumor cell neoplastic subpopulations outlined by Single-Cell transcriptomics","volume":"13","author":"Pauken","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116050_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41523-022-00445-7","article-title":"Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis","volume":"8","author":"Roth\u00e9","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib37","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.15252\/emmm.201404033","article-title":"Molecular profiling of single circulating tumor cells with diagnostic intention","volume":"6","author":"Polzer","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ejca.2025.116050_bib38","doi-asserted-by":"crossref","unstructured":"Munoz-Arcos L.S., Nicol\u00f2 E., Serafini M.S., et al: Latest Advances In Clinical Studies Of Circulating Tumor Cells In Early And Metastatic Breast Cancer, in 2023, pp 1\u201321Available from: \u3008https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644823001193\u3009.","DOI":"10.1016\/bs.ircmb.2023.07.005"},{"key":"10.1016\/j.ejca.2025.116050_bib39","doi-asserted-by":"crossref","first-page":"R43","DOI":"10.1186\/bcr3647","article-title":"International study on inter-reader variability for circulating tumor cells in breast cancer","volume":"16","author":"Ignatiadis","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2025.116050_bib40","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/1878-0261.13650","article-title":"Comprehensive characterization of circulating tumor cells and cell-free DNA in patients with metastatic melanoma","volume":"18","author":"Bos","year":"2024","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41467-024-55140-x","article-title":"Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product","volume":"16","author":"Mishra","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.116050_bib42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-024-01984-2","article-title":"Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells","volume":"23","author":"Rieckmann","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib43","doi-asserted-by":"crossref","first-page":"16580","DOI":"10.1073\/pnas.1313594110","article-title":"Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients","volume":"110","author":"Fischer","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ejca.2025.116050_bib44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12943-023-01880-1","article-title":"Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis","volume":"22","author":"Stoecklein","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2023.100132","article-title":"Cellular residual disease (CRD) in early breast cancer \u2013Expanding the concept of minimal residual disease monitoring?","volume":"3","author":"Serafini","year":"2024","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.ejca.2025.116050_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41523-021-00319-4","article-title":"Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer","volume":"7","author":"Bortolini Silveira","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111597","article-title":"Sentinel\u201d circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease","volume":"9","author":"Ilie","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2025.116050_bib48","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.3390\/cancers14143341","article-title":"Accurate screening for Early-Stage breast cancer by detection and profiling of circulating tumor cells","volume":"14","author":"Crook","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116050_bib49","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1002\/cam4.5649","article-title":"Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells","volume":"12","author":"Limaye","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.116050_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101258","article-title":"Circulating tumor cells as liquid biopsy markers in cancer patients","volume":"96","author":"Smit","year":"2024","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.ejca.2025.116050_bib51","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.3390\/cancers15153949","article-title":"Cell state and cell type: deconvoluting circulating tumor cell populations in liquid biopsies by Multi-Omics","volume":"15","author":"Welter","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116050_bib52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41416-021-01327-8","article-title":"Detection of clustered circulating tumour cells in early breast cancer","volume":"125","author":"Krol","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.116050_bib53","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ccell.2025.07.008","article-title":"Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications","volume":"43","author":"Dai","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.116050_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104696","article-title":"Isolation of circulating tumor cells","volume":"25","author":"Edd","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejca.2025.116050_bib55","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3390\/cancers14215238","article-title":"A Multi-Center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the Parsortix\u00ae PC1 system","volume":"14","author":"Cohen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116050_bib56","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41591-024-03486-6","article-title":"Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial","volume":"31","author":"Kurzeder","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116050_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2014 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116050_bib58","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with Triple-Negative breast cancer","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2025.116167","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:02:57Z","timestamp":1769792577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"alternative-id":["S0959804925009360"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116050","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International expert consensus on the clinical integration of circulating tumor cells in solid tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116050"}}